
83Designing Cost-Effectiveness into a Clinical Trial
cycle, then treatment should be stopped. The value of Erlotinib compared
with BSC/Placebo is better demonstrated in patients who develop rash after
being treated with Erlotinib for the rst 28days. Costs of treatment for rash,
as well as duration of treatment, are important, because median OS and PFS
will be higher in the patients with rash. Rash as a biomarker removes the
need for a biopsy, which might improve QoL.
3.6.14 Multinational and Multicentre Trials
This trial was a UK multicentre trial, and costs between centres were
compared for both treatment groups. Costs were modelled usin